
Hereditary Plasma Clotting Factor Disorders and their Management — Russian
Also Available In: English, Spanish This is not an official WFH translation. This resource has been translated with permission by
Год: 2016
Язык: Russian
Этот материал также есть на других языках: Арабский Английский Французский Испанский Китайский (упрощенный)
Автор(ы): World Federation of Hemophilia
Формат: Документ
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

Also Available In: English, Spanish This is not an official WFH translation. This resource has been translated with permission by

Also Available In: English, Spanish This is not an official WFH translation. This resource has been translated with permission by

Also Available In: Japanese Access to home treatment reduces the economic impact on healthcare systems and improves the quality of

Also Available In: Japanese Treating people with hemophilia with safe, regulated plasma-derived factor concentrate directly reduces the social and economic

Also Available In: Japanese This fact sheet demonstrates the benefits of providing basic treatment and care to people with hemophilia.

Also Available In: English, Spanish This is not an official WFH translation. This resource has been translated with permission by